In the USA, the world’s first vaccine against the RSV virus was approved
[ad_1]
The world’s first vaccine against respiratory syncytial virus (RSV) was approved in the USA. This virus is one of the leading causes of respiratory diseases in infants and children under 5 years of age, but it also affects adults. In the USA alone, thousands of deaths caused by the consequences of the disease are registered annually.
The main US regulatory body overseeing pharmacology – The US Food and Drug Administration (FDA) – approved the vaccine Arexvy, developed by the pharmaceutical company GSK. Its efficiency is estimated at 82.6 percent. Side effects are minimal and mainly include pain at the injection site.
Next, the vaccine will have to undergo approval in other regulatory bodies. It is expected that in a few months Arexvy will be available for use in people over 60 years old.
The respiratory syncytial virus affects the bronchi and lungs. In the USA, 100-300 children under the age of five die from it every year, and more than 50 thousand children end up in hospitals. In adults, it is a special danger for the elderly, people with reduced immunity and chronic diseases. In general, six to ten thousand people over the age of 65 die from it every hour in the United States, and 60 to 120 thousand require hospitalization. In adults without concomitant diseases, it often passes like a common cold, but can leave consequences in the form of months-long weakness and a debilitating cough.
The development of vaccines against RSV has been introduced in many countries of the world for more than 60 years, since its discovery in 1955.
[ad_2]
Original Source Link
